73158-83-5

Basic information

• Product Name: 4-hydroxyphenylacetic acid N-hydroxysuccinimide ester
• Synonyms: 4-hydroxyphenylacetic acid N-hydroxysuccinimide ester
• CAS NO: 73158-83-5
• Molecular Weight: 249.223
• Mol File: 73158-83-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-hydroxyphenylacetic acid N-hydroxysuccinimide ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxyphenylacetic acid N-hydroxysuccinimide ester(73158-83-5)
• EPA Substance Registry System: 4-hydroxyphenylacetic acid N-hydroxysuccinimide ester(73158-83-5)

Safety Data

• Hazardous Substances Data: 73158-83-5(Hazardous Substances Data)

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 156-38-7 4-hydroxyphenylacetate 
• 538-75-0 dicyclohexyl-carbodiimide 

Downstream Products

• 199541-47-4 {(S)-2-[2-(4-Hydroxy-phenyl)-acetylamino]-hexanoylamino}-acetic acid methyl ester 
• 1394822-04-8 tert-butyl-4-(2-(2-(4-(diethoxyphosphoryloxy)phenyl)acetamido)ethyl)-1H-imidazole-1-carboxylate 
• 1394821-81-8 tert-butyl 4-(2-(2-(4-hydroxyphenyl)acetamido)ethyl)-1H-imidazole-1-carboxylate 
• 1027945-78-3 (4-Phosphonooxy-phenyl)-acetic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 102131-35-1 2,2,5,5-Tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid {3-[2-(4-hydroxy-phenyl)-acetylamino]-propyl}-amide 

Relevant articles and documents

PCR incorporation of dUMPs modified with aromatic hydrocarbon substituents of different hydrophilicities: Synthesis of C5-modified dUTPs and PCR studies using Taq, Tth, Vent (exo-) and Deep Vent (exo-) polymerases

Deoxyuridine triphosphate derivatives (dUTPs) modified at the C5 position of the pyrimidine ring with various aromatic hydrocarbon substituents of different hydrophilicities have been synthesized. The aromatic hydrocarbon substituents were attached to dUTPs via a CH[dbnd]CH[sbnd]CH2[sbnd]NHCO[sbnd]CH2 linker. The efficiency of the PCR incorporation of modified dUMPs using Taq, Tth, Vent (exo-) and Deep Vent (exo-) polymerases and a model DNA template containing one, two and three adjacent adenine nucleotides at three different sites within the sequence was investigated. For all the polymerases used, the yield of the modified PCR product was significantly increased with increasing hydrophilicity of the aromatic hydrocarbon substituent. In particular, for the above polymerases, the efficiency of the incorporation of dUMPs modified with the most hydrophilic of the studied aromatic hydrocarbon substituents, a 4-hydroxyphenyl residue, was 60–85% of the efficiency of dTMP incorporation. At the same time, the relative efficiencies of the incorporation of dUMPs modified with 2-, 4-methoxyphenyl, phenyl and 4-nitrophenyl substituents ranged from 20 to 50% and were 2–18% for the 1-naphthalene and 4-biphenyl groups, which were the most hydrophobic of the studied aromatic hydrocarbon substituents.

PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF

The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating.

Cell adhesion inhibitors

The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.